Guggenheim Capital LLC Acquires 1,140 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Guggenheim Capital LLC increased its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 5.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 22,552 shares of the medical research company’s stock after buying an additional 1,140 shares during the period. Guggenheim Capital LLC’s holdings in IQVIA were worth $4,432,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Synergy Asset Management LLC bought a new position in shares of IQVIA in the fourth quarter worth $33,000. Lee Danner & Bass Inc. purchased a new stake in IQVIA during the 4th quarter worth about $44,000. Zions Bancorporation N.A. boosted its stake in IQVIA by 55.2% in the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company’s stock worth $47,000 after purchasing an additional 85 shares during the period. Versant Capital Management Inc grew its holdings in IQVIA by 46.0% during the 4th quarter. Versant Capital Management Inc now owns 295 shares of the medical research company’s stock valued at $58,000 after buying an additional 93 shares in the last quarter. Finally, SBI Securities Co. Ltd. purchased a new stake in shares of IQVIA in the fourth quarter worth about $60,000. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Trading Down 3.2 %

NYSE:IQV opened at $143.66 on Friday. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a 12 month low of $135.97 and a 12 month high of $252.88. The company has a 50-day moving average price of $176.42 and a 200-day moving average price of $196.86. The stock has a market cap of $25.33 billion, a price-to-earnings ratio of 19.15, a P/E/G ratio of 1.99 and a beta of 1.46.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Equities analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Analyst Upgrades and Downgrades

IQV has been the topic of a number of analyst reports. UBS Group decreased their target price on shares of IQVIA from $260.00 to $255.00 and set a “buy” rating on the stock in a report on Friday, February 7th. Robert W. Baird reduced their target price on IQVIA from $212.00 to $210.00 and set a “neutral” rating for the company in a research report on Tuesday, January 21st. StockNews.com lowered IQVIA from a “buy” rating to a “hold” rating in a report on Wednesday, March 12th. Stephens initiated coverage on shares of IQVIA in a research note on Friday, December 20th. They issued an “overweight” rating and a $250.00 price target for the company. Finally, Barclays reaffirmed an “equal weight” rating and set a $170.00 price objective (down from $235.00) on shares of IQVIA in a report on Thursday, April 10th. Six research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, IQVIA has a consensus rating of “Moderate Buy” and a consensus price target of $241.50.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.